Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24177004 | 0.93 | HSD17B10 (0.44) | HSD17B10SIGMAR1SMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL15499048 | 0.87 | HSD17B10 (0.48) | HSD17B10SIGMAR1SMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL1142728 | 0.87 | HSD17B10 (0.48) | HSD17B10SIGMAR1SMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL10060138 | 0.87 | HSD17B10 (0.48) | HSD17B10SIGMAR1SMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL15499754 | 0.87 | HSD17B10 (0.48) | HSD17B10SIGMAR1SMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL10317239 | 0.87 | HSD17B10 (0.48) | HSD17B10SIGMAR1SMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL9119001 | 0.87 | HSD17B10 (0.48) | HSD17B10SIGMAR1SMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL12018111 | 0.87 | HSD17B10 (0.48) | HSD17B10SIGMAR1SMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL22661894 | 0.87 | HSD17B10 (0.48) | HSD17B10SIGMAR1SMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL16645315 | 0.86 | HSD17B10 (0.41) | HSD17B10SIGMAR1S1PR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393809-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS | Universität Heidelbert (DE) | 2021-12-23 | — | — | US | disclosed |
| US-9776977-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-10-03 | — | — | US | disclosed |
| US-20120009121-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009121-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | FOLH1, KLK3, PSMA2 | HSD17B10 2398/4885SIGMAR1 4119/4885SMN1; SMN2 4026/4885 |
| US-20210393809-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS | KLK3, PSMA3, FOLH1 | HSD17B10 3146/4885SIGMAR1 939/4885SMN1; SMN2 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.